Revolution Medicines(RVMD) - 2021 Q3 - Earnings Call Presentation

RMC-6291 (KRASG12C Inhibitor) - RMC-6291 is a potent and selective inhibitor of KRASG12C, with a median EC50 of 0.1 nM in KRASG12C cells and a selectivity of 12,700-fold over non-KRASG12C cells[23] - In a mouse clinical trial with KRASG12C NSCLC xenografts, RMC-6291 achieved a 68% overall response rate (ORR) (13/19)[29] - RMC-6291 is active against all reported second-site KRASG12C(OFF) inhibitor resistance mutations[40] - The IND submission for RMC-6291 is projected for 1H2022[44] RMC-6236 (RASMULTI Inhibitor) - RMC-6236 is a potent, oral, RAS-selective tri-complex RASMULTI(ON) inhibitor, with IC50 values ranging from 0.4-3 nM for pERK and 1-27 nM for CTG in RAS-dependent cells[48] - In preclinical studies, RMC-6236 demonstrated a 62% ORR (8/13) and 100% disease control rate (DCR) (13/13) in diverse RAS pathway mutant tumors[53] - RMC-6236 drove regressions in KRASG12X PDAC tumor models in vivo, with a 57% ORR (8/14) and 86% DCR (12/14)[57] - RMC-6236 also drove regressions in KRASG12X CRC tumor models in vivo, with a 38% ORR (5/13) and 54% DCR (7/13)[61] - The IND submission for RMC-6236 is projected for 1H2022[70] Financial Status - As of September 30, 2021, Revolution Medicines had $608.7 million in cash, cash equivalents, and marketable securities[114] - The company projects a 2021 GAAP net loss of $170 million to $190 million, including approximately $20 million in non-cash stock-based compensation[114]